[1]
Gohlke P, Jürgensen T, von Kügelgen S, Unger T. Candesartan cilexetil: development and preclinical studies. Drugs of today (Barcelona, Spain : 1998). 1999 Feb:35(2):105-15
[PubMed PMID: 12973413]
[2]
Zhao D, Liu H, Dong P. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993). 2019:41(1):75-79. doi: 10.1080/10641963.2018.1445750. Epub 2018 Mar 28
[PubMed PMID: 29589977]
Level 1 (high-level) evidence
[3]
Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. Journal of human hypertension. 1997 Sep:11 Suppl 2():S91-5
[PubMed PMID: 9331018]
[4]
Hosaka M, Metoki H, Satoh M, Ohkubo T, Asayama K, Kikuya M, Inoue R, Obara T, Hirose T, Imai Y, J-HOME-CARD Study Group. Randomized trial comparing the velocities of the antihypertensive effects on home blood pressure of candesartan and candesartan with hydrochlorothiazide. Hypertension research : official journal of the Japanese Society of Hypertension. 2015 Oct:38(10):701-7. doi: 10.1038/hr.2015.64. Epub 2015 Jun 4
[PubMed PMID: 26041602]
Level 1 (high-level) evidence
[5]
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European journal of heart failure. 2018 Aug:20(8):1230-1239. doi: 10.1002/ejhf.1149. Epub 2018 Feb 12
[PubMed PMID: 29431256]
[6]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[7]
Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL Jr, Yancy CW. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2023 May 9:81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19
[PubMed PMID: 37137593]
Level 3 (low-level) evidence
[8]
Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, Hopper I, Julius S, Pitt B, Reid CM, Devereux RB, Zannad F. Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension (Dallas, Tex. : 1979). 2020 Jan:75(1):23-32. doi: 10.1161/HYPERTENSIONAHA.119.14057. Epub 2019 Dec 2
[PubMed PMID: 31786973]
[9]
Fu H, Hosomi N, Pelisch N, Nakano D, Liu G, Ueno M, Miki T, Masugata H, Sueda Y, Itano T, Matsumoto M, Nishiyama A, Kohno M. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. Journal of hypertension. 2011 Nov:29(11):2210-9. doi: 10.1097/HJH.0b013e32834bbb30. Epub
[PubMed PMID: 21934531]
[10]
Takao T, Horino T, Kagawa T, Matsumoto R, Shimamura Y, Ogata K, Inoue K, Taniguchi Y, Taguchi T, Morita T, Terada Y. Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells. Journal of nephrology. 2011 Mar-Apr:24(2):218-24
[PubMed PMID: 20890878]
[11]
Wang Z, Niu Q, Peng X, Li M, Liu K, Liu Y, Liu J, Jin F, Li X, Wei Y. Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR. International journal of cardiology. 2016 Jul 1:214():348-57. doi: 10.1016/j.ijcard.2016.04.007. Epub 2016 Apr 5
[PubMed PMID: 27085127]
[12]
Fehér G, Pusch G. [Role of antihypertensive drugs in the treatment of migraine]. Orvosi hetilap. 2015 Feb 1:156(5):179-85. doi: 10.1556/OH.2015.30056. Epub
[PubMed PMID: 25618859]
[13]
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes care. 2023 Jan 1:46(Suppl 1):S191-S202. doi: 10.2337/dc23-S011. Epub
[PubMed PMID: 36507634]
[15]
Kassem I, Sanche S, Li J, Bonnefois G, Dubé MP, Rouleau JL, Tardif JC, White M, Turgeon J, Nekka F, de Denus S. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure. Clinical and translational science. 2021 Jan:14(1):194-203. doi: 10.1111/cts.12842. Epub 2020 Aug 28
[PubMed PMID: 32702160]
[16]
Carey RM, Moran AE, Whelton PK. Treatment of Hypertension: A Review. JAMA. 2022 Nov 8:328(18):1849-1861. doi: 10.1001/jama.2022.19590. Epub
[PubMed PMID: 36346411]
[17]
Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.). 2021 Aug:74(2):1014-1048. doi: 10.1002/hep.31884. Epub
[PubMed PMID: 33942342]
[18]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub
[PubMed PMID: 30575676]
[19]
Fujii H, Nakahama H, Yoshihara F, Nakamura S, Inenaga T, Kawano Y. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. The Kobe journal of medical sciences. 2005:51(1-2):1-6
[PubMed PMID: 16199929]
[20]
Zwanzger P, Marcuse A, Boerner RJ, Walther A, Rupprecht R. Lithium intoxication after administration of AT1 blockers. The Journal of clinical psychiatry. 2001 Mar:62(3):208-9
[PubMed PMID: 11305712]
[21]
Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, Montastruc JL. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. European journal of clinical pharmacology. 2012 Nov:68(11):1533-40. doi: 10.1007/s00228-012-1283-9. Epub 2012 Apr 15
[PubMed PMID: 22527348]
[22]
Whitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, Farag YMK, Tangri N. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2023 Oct 31:38(11):2503-2516. doi: 10.1093/ndt/gfad101. Epub
[PubMed PMID: 37309038]
Level 1 (high-level) evidence
[23]
Rasmussen ER, Hallberg P, Baranova EV, Eriksson N, Karawajczyk M, Johansson C, Cavalli M, Maroteau C, Veluchamy A, Islander G, Hugosson S, Terreehorst I, Asselbergs FW, Norling P, Johansson HE, Kohnke H, Syvänen AC, Siddiqui MK, Lang CC, Magnusson PKE, Yue QY, Wadelius C, von Buchwald C, Bygum A, Alfirevic A, Maitland-van der Zee AH, Palmer CNA, Wadelius M. Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. The pharmacogenomics journal. 2020 Dec:20(6):770-783. doi: 10.1038/s41397-020-0165-2. Epub 2020 Feb 21
[PubMed PMID: 32080354]
[24]
Korkes H, Oliveira LG, Berlinck L, Borges AF, Goes FS, Watanabe S, Landman C, Sass N. PP138. Human fetal malformations associated with the use of angiotensin II receptor antagonist. Pregnancy hypertension. 2012 Jul:2(3):314-5. doi: 10.1016/j.preghy.2012.04.249. Epub 2012 Jun 13
[PubMed PMID: 26105460]
[25]
Hünseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, Körber F, Schmitt K, Welzing L, Müller A, Herkenrath P, Hoppe B, Gortner L, Roth B, Kattner E, Schaible T. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klinische Padiatrie. 2011 Jan:223(1):10-4. doi: 10.1055/s-0030-1269895. Epub 2011 Jan 26
[PubMed PMID: 21271514]
Level 3 (low-level) evidence
[26]
Shibata S, Matsunaga M, Oikawa M, Nitahara K, Higa K. [Severe hypotension after induction of general anesthesia in a patient receiving an angiotensin II receptor antagonist and an alpha-blocker]. Masui. The Japanese journal of anesthesiology. 2005 Jun:54(6):670-2
[PubMed PMID: 15966388]
[27]
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney international. 2020 Oct:98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. Epub
[PubMed PMID: 32998798]
Level 1 (high-level) evidence
[28]
Prasa D, Hoffmann-Walbeck P, Barth S, Stedtler U, Ceschi A, Färber E, Genser D, Seidel C, Deters M. Angiotensin II antagonists - an assessment of their acute toxicity. Clinical toxicology (Philadelphia, Pa.). 2013 Jun:51(5):429-34. doi: 10.3109/15563650.2013.800875. Epub 2013 May 22
[PubMed PMID: 23692319]
[29]
Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. Journal of the American College of Cardiology. 2007 Nov 13:50(20):1959-66
[PubMed PMID: 17996561]
[30]
Hetterich N, Lauterbach E, Stürer A, Weilemann LS, Lauterbach M. Toxicity of antihypertensives in unintentional poisoning of young children. The Journal of emergency medicine. 2014 Aug:47(2):155-62. doi: 10.1016/j.jemermed.2014.02.006. Epub 2014 Apr 18
[PubMed PMID: 24746907]
[31]
Donald BJ, King TD, Phillips BL, Jones K, Barham A, Watson J, Batson J. Physician-Pharmacist Collaborative Drug Therapy Management in Pediatric Hypertension. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2023:28(3):204-211. doi: 10.5863/1551-6776-28.3.204. Epub 2023 Jun 2
[PubMed PMID: 37303761]